{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T04:25:09Z","timestamp":1764044709939},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Research Grant from Gangnam Severance Hospital, Yonsei University College of Medicine","award":["3-2020-0315"],"award-info":[{"award-number":["3-2020-0315"]}]},{"name":"Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT","award":["NRF-2018R1A6A1A03023718","NRF-2019R1I1A1A01058889","NRF-2021R1A2C1012853","NRF-2022R1A2C1013201"],"award-info":[{"award-number":["NRF-2018R1A6A1A03023718","NRF-2019R1I1A1A01058889","NRF-2021R1A2C1012853","NRF-2022R1A2C1013201"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1245\/s10434-022-12358-7","type":"journal-article","created":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T23:06:45Z","timestamp":1661900805000},"page":"8583-8592","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacologic Effects of Oxaliplatin Instability in Chloride-Containing Carrier Fluids on the\u00a0Hyperthermic Intraperitoneal Chemotherapy to Treat Colorectal Cancer In Vitro and In Vivo"],"prefix":"10.1245","volume":"29","author":[{"given":"Eun Jung","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhyun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharif Md","family":"Abuzar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Su","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Joo","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Hyuk","family":"Baik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,30]]},"reference":[{"key":"12358_CR1","doi-asserted-by":"publisher","first-page":"10765","DOI":"10.1021\/jp800476b","volume":"112","author":"ME Alberto","year":"2008","unstructured":"Alberto ME, Lucas MF, Pavelka M, Russo N. The degradation pathways in chloride medium of the third-generation anticancer drug oxaliplatin. J Phys Chem B. 2008;112:10765\u20138.","journal-title":"J Phys Chem B."},{"key":"12358_CR2","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1245\/s10434-008-9967-1","volume":"15","author":"JH Stewart","year":"2008","unstructured":"Stewart JH, Shen P, Russell G, et al. A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol. 2008;15:2137\u201345.","journal-title":"Ann Surg Oncol."},{"key":"12358_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1525-1438.2007.00809.x","volume":"17","author":"K Fujiwara","year":"2007","unstructured":"Fujiwara K, Armstrong D, Morgan M, Markman M. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer. 2007;17:1\u201320.","journal-title":"Int J Gynecol Cancer."},{"key":"12358_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrclinonc.2009.217","volume":"7","author":"WP Ceelen","year":"2010","unstructured":"Ceelen WP, Flessner MF. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nature Rev Clin Oncol. 2010;7:108\u201315.","journal-title":"Nature Rev Clin Oncol."},{"key":"12358_CR5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4251\/wjgo.v2.i2.109","volume":"2","author":"TD Yan","year":"2010","unstructured":"Yan TD, Cao CQ, Munkholm-Larsen S. A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy. World J Gastrointest Oncol. 2010;2:109\u201316.","journal-title":"World J Gastrointest Oncol."},{"key":"12358_CR6","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1245\/s10434-010-1210-1","volume":"18","author":"NM Rueth","year":"2011","unstructured":"Rueth NM, Murray SE, Huddleston SJ, et al. Severe electrolyte disturbances after hyperthermic intraperitoneal chemotherapy: oxaliplatin versus mitomycin C. Ann Surg Oncol. 2011;18:174\u201380.","journal-title":"Ann Surg Oncol."},{"key":"12358_CR7","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1245\/s10434-007-9648-5","volume":"15","author":"WP Ceelen","year":"2008","unstructured":"Ceelen WP, Peeters M, Houtmeyers P, Breusegem C, De Somer F, Pattyn P. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Ann Surg Oncol. 2008;15:535\u201341.","journal-title":"Ann Surg Oncol."},{"key":"12358_CR8","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1245\/s10434-016-5143-1","volume":"23","author":"T Charrier","year":"2016","unstructured":"Charrier T, Passot G, Peron J, et al. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. Ann Surg Oncol. 2016;23:2315\u201322.","journal-title":"Ann Surg Oncol."},{"key":"12358_CR9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ejso.2006.03.004","volume":"32","author":"D Elias","year":"2006","unstructured":"Elias D, Raynard B, Bonnay M, Pocard M. Heated intraoperative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: pharmacologic studies. Eur J Surg Oncol. 2006;32:607\u201313.","journal-title":"Eur J Surg Oncol."},{"key":"12358_CR10","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1023\/A:1008213732429","volume":"9","author":"E Raymond","year":"1998","unstructured":"Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998;9:1053\u201371.","journal-title":"Ann Oncol."},{"key":"12358_CR11","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejso.2018.10.542","volume":"45","author":"W Ceelen","year":"2019","unstructured":"Ceelen W. HIPEC with oxaliplatin for colorectal peritoneal metastasis: the end of the road? Eur J Surg Oncol. 2019;45:400\u20132.","journal-title":"Eur J Surg Oncol."},{"key":"12358_CR12","first-page":"1753","volume":"27","author":"ZD Lv","year":"2012","unstructured":"Lv ZD, Yang ZC, Wang HB, et al. The cytotoxic effect of TGF-\u03b21 on mesothelial cells via apoptosis in early peritoneal carcinomatosis. Oncol Rep. 2012;27:1753\u20138.","journal-title":"Oncol Rep."},{"key":"12358_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomizedsed, open-label, phase 3 trial. Lancet Oncol. 2021;22:256\u201366.","journal-title":"Lancet Oncol."},{"key":"12358_CR14","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3393\/ac.2021.00920.0131","volume":"37","author":"YJ Kim","year":"2021","unstructured":"Kim YJ, Kim CH. Treatment for peritoneal metastasis of patients with colorectal cancer. Ann Coloproctol. 2021;37:425\u201333.","journal-title":"Ann Coloproctol."},{"key":"12358_CR15","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.1245\/s10434-018-6628-x","volume":"25","author":"EJ Park","year":"2018","unstructured":"Park EJ, Ahn J, Gwak SW, Park KS, Baik SH, Hwang SJ. Pharmacologic properties of the carrier solutions for hyperthermic intraperitoneal chemotherapy: comparative analyses between water and lipid carrier solutions in the rat model. Ann Surg Oncol. 2018;25:3185\u201392.","journal-title":"Ann Surg Oncol."},{"key":"12358_CR16","first-page":"303","volume":"5","author":"D Du Bois","year":"1989","unstructured":"Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5:303\u201311.","journal-title":"Nutrition."},{"issue":"3 Pt 2","key":"12358_CR17","first-page":"F425","volume":"248","author":"MF Flessner","year":"1985","unstructured":"Flessner MF, Fenstermacher JD, Dedrick RL, Blasberg RG. A distributed model of peritoneal-plasma transport: tissue concentration gradients. Am J Physiol. 1985;248(3 Pt 2):F425\u201335.","journal-title":"Am J Physiol."},{"key":"12358_CR18","first-page":"227","volume":"1","author":"E Raymond","year":"2002","unstructured":"Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther. 2002;1:227\u201335.","journal-title":"Mol Cancer Ther."},{"key":"12358_CR19","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1002\/jps.21732","volume":"98","author":"E Jerremalm","year":"2009","unstructured":"Jerremalm E, Wallin I, Ehrsson H. New insights into the biotransformation and pharmacokinetics of oxaliplatin. J Pharm Sci. 2009;98:3879\u201385.","journal-title":"J Pharm Sci."},{"key":"12358_CR20","first-page":"3500","volume":"54","author":"EL Mamenta","year":"1994","unstructured":"Mamenta EL, Poma EE, Kaufmann WK, Delmastro DA, Grady HL, Chaney SG. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 1994;54:3500\u20135.","journal-title":"Cancer Res."},{"key":"12358_CR21","first-page":"595","volume":"10","author":"FR Luo","year":"1998","unstructured":"Luo FR, Wyrick SD, Chaney SG. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol Res. 1998;10:595\u2013603.","journal-title":"Oncol Res."},{"key":"12358_CR22","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1023\/B:PHAM.0000026444.67883.83","volume":"21","author":"E Jerremalm","year":"2004","unstructured":"Jerremalm E, Hedeland M, Wallin I, Bondesson U, Ehrsson H. Oxaliplatin degradation in the presence of chloride: identification and cytotoxicity of the monochloro monooxalato complex. Pharm Res. 2004;21:891\u20134.","journal-title":"Pharm Res."},{"key":"12358_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/471205","volume":"2012","author":"PH Sugarbaker","year":"2012","unstructured":"Sugarbaker PH, Stuart OA, Eger C. Pharmacokinetics of hyperthermic intrathoracic chemotherapy following pleurectomy and decortication. Gastroenterol Res Pract. 2012;2012:471205.","journal-title":"Gastroenterol Res Pract."},{"key":"12358_CR24","doi-asserted-by":"publisher","first-page":"4874","DOI":"10.1245\/s10434-020-08330-y","volume":"27","author":"RJ Torphy","year":"2020","unstructured":"Torphy RJ, Stewart C, Sharma P, et al. Dextrose-containing carrier solution for hyperthermic intraperitoneal chemotherapy: increased intraoperative hyperglycemia and postoperative complications. Ann Surg Oncol. 2020;27:4874\u201382.","journal-title":"Ann Surg Oncol."},{"key":"12358_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jss.2020.06.055","volume":"256","author":"PT Lindsey","year":"2020","unstructured":"Lindsey PT, Martin RCG II, Scoggins CR, et al. Impact of perfusate glucose concentration on perioperative outcomes in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Res. 2020;256:206\u201311.","journal-title":"J Surg Res."},{"key":"12358_CR26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jamcollsurg.2017.12.027","volume":"226","author":"EA Levine","year":"2018","unstructured":"Levine EA, Votanopoulos KI, Shen P, et al. A multicenter randomized trial to evaluate hematologic toxicities after hyperthermic intraperitoneal chemotherapy with oxaliplatin or mitomycin in patients with appendiceal tumors. J Am Coll Surg. 2018;226:434\u201343.","journal-title":"J Am Coll Surg"},{"key":"12358_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijpharm.2014.12.025","volume":"479","author":"AM Mehta","year":"2015","unstructured":"Mehta AM, Van den Hoven JM, Rosing H, et al. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharmaceutics. 2015;479:23\u20137.","journal-title":"Int J Pharmaceutics."},{"key":"12358_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/annonc\/mdf019","volume":"13","author":"D Elias","year":"2002","unstructured":"Elias D, Bonnay M, Puizillou JM, et al. Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol. 2002;13:267\u201372.","journal-title":"Ann Oncol."},{"key":"12358_CR29","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/ans.15424","volume":"89","author":"CE Koh","year":"2019","unstructured":"Koh CE, Ansari N, Morris D, Moran B. Beware misrepresentation of PRODIGE 7: danger of throwing out the cytoreductive surgery baby with the hyperthermic intraperitoneal chemotherapy bathwater. ANZ J Surg. 2019;89:992\u20134.","journal-title":"ANZ J Surg."},{"key":"12358_CR30","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1007\/s11605-019-04447-y","volume":"24","author":"V Narasimhan","year":"2020","unstructured":"Narasimhan V, Warrier S, Michael M, Ramsay R, Heriot A. Oxaliplatin versus mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study. J Gastrointest Surg. 2020;24:2104\u201312.","journal-title":"J Gastrointest Surg."},{"key":"12358_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3393\/ac.2017.33.1.16","volume":"33","author":"WR Kim","year":"2017","unstructured":"Kim WR, Hur H, Min BS, Baik SH, Lee KY, Kim NK. Single-center experience with hyperthermic intraperitoneal chemotherapy. Ann Coloproctol. 2017;33:16\u201322.","journal-title":"Ann Coloproctol."},{"key":"12358_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3393\/ac.2019.04.30","volume":"36","author":"SJ Roh","year":"2020","unstructured":"Roh SJ, Park SC, Choi J, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with mitomycin C used for colorectal peritoneal carcinomatosis. Ann Coloproctol. 2020;36:22\u20139.","journal-title":"Ann Coloproctol."},{"key":"12358_CR33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejso.2017.10.216","volume":"44","author":"WJ van Eden","year":"2018","unstructured":"van Eden WJ, Kok NFM, Woensdregt K, Huitema ADR, Boot H, Aalbers AGJ. Safety of intraperitoneal mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC. Eur J Surg Oncol. 2018;44:220\u20137.","journal-title":"Eur J Surg Oncol."},{"key":"12358_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3109\/1061186X.2015.1051049","volume":"24","author":"P Kumari","year":"2016","unstructured":"Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target. 2016;24:179\u201391.","journal-title":"J Drug Target."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12358-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-12358-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-12358-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T03:02:42Z","timestamp":1667876562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-12358-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,30]]},"references-count":34,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["12358"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-12358-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,30]]},"assertion":[{"value":"23 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"DISCLOSURES"}}]}}